Cedars Sinai Research Updates in Lymphoma 2025

Cedars Sinai Research Updates in Lymphoma 2025

$40.00

+ Include: 4 videos + 22 pdfs, size: 6.5 GB

+ Target Audience: hematologists, oncologists, pathologists

Description

+ Include: 4 videos + 22 pdfs, size: 6.5 GB

+ Target Audience: hematologists, oncologists, pathologists

+ Sample video: contact me for sample video

+ Information:

Date & Location Saturday, October 18, 2025, 7:30 AM – Sunday, October 19, 2025, 3:00 PM PT, Cedars-Sinai Pavilion Education Center, Los Angeles, CA

Target Audience
Specialties – Hematology, Imaging, Internal Medicine, Oncology, Pathology & Laboratory Medicine, Radiation Oncology, Radiology, Surgery
Professions – Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)
Overview

This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, “How I Treat” sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.

Objectives
  1. Recognize the utility of molecular testing in the classification and treatment of lymphoma
  2. Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma
  3. Describe new treatments under development including bi specific antibodies and CART therapies
  4. Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

 

+ Topics:

Saturday, October 18, 2025

Session 1: Hot Topics in Clinical Lymphoma – Part I

Session Chair: TBD

Frontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates

8:10AM – 8:35AM

Joe Schroers-Martin, MD

Novel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates

8:35AM – 9:00AM

Matthew G. Mei, MD

Dual Targeting CART for Lymphoma

9:00AM – 9:25AM

Akil Merchant, MD

Break and Exhibits

9:25AM – 10:10AM

Session 2: Hot Topics in Clinical Lymphoma – Part II

Session Chair: Justin Darrah

T-Cell Lymphoma

10:10AM – 10:35AM

Wen-Kai Weng, MD, PhD

Role of Radiation Therapy in Lymphoma

10:35AM – 11:00AM

Parag Sanghvi, MD

Lightning Round
Lightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)

11:00AM – 11:30AM

Lunch and Networking
Lunch and Exhibits

11:30AM – 12:15PM

Session 3: Keynote & Basic Science Insights

Session Chair: Akil Merchant, MD

KEYNOTE ADDRESS: Spatial Profiling in Lymphoma Transformers: More than Meets the Eye

12:15PM – 1:00PM

Mina Xu, MD

Microenvironment in Non-Hodgkin Lymphoma

1:00PM – 1:20PM

Anthony R Colombo, PhD

Hidden Opponents: The DLBCL Microenvironment

1:20PM – 1:40PM

David Russler-Germain, MD, PhD

Metabolic Profiling and Modulation of the Lymphoma Microenvironment

1:40PM – 2:00PM

Akil Merchant, MD

Break and Exhibits

2:00PM – 2:20PM

Session 4: Next Generation Diagnostics and Biomarkers

Session Chair: Joseph C. Lownik, MD

Lymphoma Biomarker Development: Lessons Learned from Gene Expression Profiling

2:20PM – 2:50PM

Lisa M Rimsza, MD

Developing an Automated Multiplex IF for Diagnostic/Biomarker Use in Lymphoma

2:50PM – 3:10PM

Joseph C. Lownik, MD

Role of ct DNA in Lymphoma

3:10PM – 3:30PM

Brian Sworder, MD, PhD

Assessments and Therapies for Older Patients with Aggressive Lymphomas

3:30PM – 3:50PM

Elizabeth Brem, MD

Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in DLBCL

3:50PM – 4:10PM

Sean R Corcoran , MD, PhD

Adjourn

4:10PM – 4:15PM

Networking Reception
Networking Reception

4:15PM – 5:30PM

Sunday, October 19, 2025

Session 1: CAR-T Cell Therapy: Managing Complex Toxicities

Session Chair: Hitomi Hosoya, MD, PhD

Mechanisms of Neurotoxicity with IEC and Bispecific Therapies

8:00AM – 8:20AM

Juliane Gust, MD, PhD

IEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management

8:20AM – 8:40AM

Hrishikesh Srinagesh, MD

Prophylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches

8:40AM – 9:00AM

Caspian Oliai, MD

Secondary and T-cell Malignancies after CAR T-cell Therapy

9:00AM – 9:20AM

Hitomi Hosoya, MD, PhD

Break and Exhibits

9:20AM – 9:35AM

Session 2: Clinical Debate–What is the Optimal Bridging Strategy for CAR-T Therapy

Session Chair: Justin Darrah, MD

Intro: Why bridging?

9:35AM – 9:40AM

Justin Darrah, MD

Role of Bispecifics as Bridging

9:40AM – 9:50AM

Justin Darrah, MD

Radiation as Bridging

9:50AM – 10:00AM

Parag Sanghvi, MD

Optimal Chemotherapy for Bridging

10:00AM – 10:10AM

David R. Oveisi, MD

Debate and Discussion

10:10AM – 10:35AM

BREAK/EXHIBITS

10:35AM – 11:05AM

Session 3: Next Generation Cellular Therapies for Lymphoma and Beyond (Non Accredited)

Session Chair: Yvonne Chen, PhD

Novel CART for Solid Tumors

11:05AM – 11:25AM

Yvonne Chen, PhD

Innovations in TIL Therapy

11:25AM – 11:50AM

Giri Ramsingh , MD

Macrophage Based Therapies

11:50AM – 12:10PM

Ann Liu, Other

Engineered Protein Circuits for Cancer Therapy

12:10PM – 12:30PM

Michael B. Elowitz, PhD

Closing and Lunch

12:30PM – 12:35PM

Reviews

There are no reviews yet.

Be the first to review “Cedars Sinai Research Updates in Lymphoma 2025”

Your email address will not be published. Required fields are marked *

Related Products